IOBT - IO Biotech Inc

https://www.iobiotech.com

Recent News

IO Biotech Announces Participation in Upcoming Investor Conferences - IO Biotech ( NASDAQ:IOBT )

Benzinga • 1 week, 4 days ago • score: -0.16

NEW YORK, Sept. 04, 2025 ( GLOBE NEWSWIRE ) -- IO Biotech IOBT, a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, announced today that members of its senior management team will provide a corporate update and participate in ...

Bearish

IO Biotech Announces Participation in Upcoming Investor Conferences

GlobeNewswire • 1 week, 4 days ago • score: -0.16

NEW YORK, Sept. 04, 2025 ( GLOBE NEWSWIRE ) -- IO Biotech ( Nasdaq: IOBT ) , a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, announced today that members of its senior management team will provide a corporate update and ...

Bullish

IO Biotech, Inc. ( IOBT ) Upgraded to Buy: Here's What You Should Know

Zacks Commentary • 1 week, 4 days ago • score: 0.35

IO Biotech, Inc. (IOBT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Neutral

IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® ( pembrolizumab ) as a First-Line Treatment for Patients with Advanced Melanoma

GlobeNewswire • 1 month ago • score: 0.00

IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial ...

Bullish

IO Biotech, Inc. ( IOBT ) Just Flashed Golden Cross Signal: Do You Buy?

Zacks Commentary • 3 months, 2 weeks ago • score: 0.50

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

Neutral

IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference

Business Insider • 3 months, 3 weeks ago • score: -0.03

NEW YORK, May 20, 2025 ( GLOBE NEWSWIRE ) -- IO Biotech ( Nasdaq: IOBT ) , a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, announced today that Mai-Britt Zocca, PhD, the company's President and CEO, along with Amy ...

Neutral

IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference

GlobeNewswire • 3 months, 3 weeks ago • score: -0.06

Neutral

IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights

Business Insider • 4 months ago • score: 0.07

• Primary endpoint of pivotal Phase 3 trial ( IOB-013/KN-D18 ) of lead investigational therapeutic cancer vaccine in patients with advanced melanoma still expected to readout in third quarter of 2025 • Data presented at recent congresses reinforces the potential of the company's T-Win candidates ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

None

52W High

$2.79

52W Low

$0.66

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.41

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

1.36

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

80.70

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

0.36%

Institutions (25–75% balanced)

63.84%

Shares Outstanding

65,881,000

Float

34,636,900

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

Gross Profit (TTM)

-2,587,000

EPS (TTM)

-1.58

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-2.13%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Value

N/A

Trend

—

Signal Cross

No cross

As of

—